Definitive evidence that combined SGLT2 inhibitor and GLP-1RA therapy translates their mechanistic promise into measured reductions in atrial fibrosis will require prospective studies, but current data support their early deployment within comprehensive HF care. This evidence concerns the gene SLC5A2 and hydrops fetalis.